Ticker

Approval in severe-to-profound and profound  OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers

BridgeBio Pharma, Inc. has surged 130% since last year, now trading at a $14.4bn market cap, driven by optimism around its pipeline and ATTR-CM drug Attruby. Attruby posted $362m in 2025 sales but faces stiff competition from Pfizer and Alnylam, with future generic threats and no 2026 revenue guidance provided. BBIO reported a 2025 net loss of $725m on $502m revenue, highlighting ongoing high R&D and SG&A spending…

Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.

PALO ALTO, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.

Spider silk's extraordinary combination of strength, elasticity, toughness, biocompatible, biodegradable, and low weight, properties that outperform Kevlar